Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
Rhea-AI Summary
Protalix BioTherapeutics (NYSE American: PLX) will release its second quarter 2026 financial results and provide a business update on Wednesday, August 12, 2026. Management will host a conference call and live webcast at 8:00 a.m. Eastern Daylight Time to review financial, corporate, and regulatory developments.
Investors can join via toll-free, international, or Israeli dial-in numbers using Conference ID 13761985, or through a webcast accessible from the company’s investor relations events page. A replay will be available for two weeks on the company’s website.
Positive
- None.
Negative
- None.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | Q1 earnings date | Neutral | +3.1% | Scheduled first-quarter results and business update for May 13, 2026 |
| Mar 11 | FY2025 earnings date | Neutral | -0.3% | Scheduled fiscal-year results and business update for March 18, 2026 |
| Nov 06 | Q3 earnings date | Neutral | -6.7% | Scheduled third-quarter results and business update for November 13, 2025 |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Matched earnings-date notices produced mixed reactions, with one positive and two negative events; the provided average move was -1.33%.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to host conference call and webcast at 8:00 a.m. EDT
CARMIEL,
Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments.
Conference Call Details:
Date: | Wednesday, August 12, 2026 |
Time: | 8:00 a.m. Eastern Daylight Time (EDT) |
Toll Free: | 1-877-423-9813 |
International: | 1-201-689-8573 |
Israeli Toll Free: | 1-809-406-247 |
Conference ID: | 13761985 |
Call me™: |
The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.
Webcast Details:
The conference will be webcast live from the Protalix website and will be available via the following links:
Company Link: | |
Webcast Link: | |
Conference ID: | 13761985 |
Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases. Protalix has researched, developed, and currently manufactures two enzyme replacement therapies that are currently available in multiple markets. These therapies are recombinant therapeutic proteins expressed through Protalix's proprietary plant cell-based expression system, ProCellEx®. ProCellEx is a unique plant cell-based system that enables Protalix to produce recombinant proteins in an industrial-scale manner with no exposure to mammalian cells. Protalix is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa, Elelyso®, for the treatment of Gaucher disease, excluding in Brazil where Protalix retains full rights.
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio® which was approved by both the FDA and the European Medicines Agency (EMA) in May 2023. Protalix's development pipeline includes, among others, two proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; and PRX–119, a plant cell-expressed long-acting DNase I for the treatment of NETs-related diseases. To learn more, please visit www.protalix.com.
Investor Contact
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-second-quarter-2026-financial-results-and-business-update-on-august-12-2026-302843662.html
SOURCE Protalix BioTherapeutics, Inc.